Guides · Prescription · off-label
For weight interventions generally, the wider Philippine picture sits in the diet pills filing and the GLP-1 price tracker.
Metformin hydrochloride is sold in the Philippines as a prescription medicine under several brand names. The Watsons Philippines metformin product pages, checked in August 2026, mark every listing prescription required.
The labelled indication is type 2 diabetes mellitus. Depending on the specific product, the label covers use as monotherapy or alongside other glucose-lowering agents in adults, and in some presentations in adolescents. Metformin labels do not list weight reduction, obesity or appetite control as an indication.
So weight use is off-label. What off-label means is that the regulator has not evaluated the drug for that purpose, the manufacturer cannot promote it for that purpose, and the responsibility sits with the prescriber rather than being backed by a label. A drug being on the shelf is not the same as a drug being approved for a given use.
The best long-run data on metformin and body weight does not come from a weight-loss trial at all. It comes from the Diabetes Prevention Program and its follow-up study, which enrolled adults with prediabetes and tracked them for years. The weight figures were collected without anyone trying to make a weight drug look good.
| Measure | Metformin | Placebo |
|---|---|---|
| Weight change, DPP double-blind phase | About 2.1% of body weight | About 0.02% |
| Approximate absolute loss at year 1 | Around 2.7 kg | Negligible |
| Long-term, out to about 10 years | About 2.0%, roughly 1.9 kg | About 0.2% |
| Highly adherent participants | About 3.5%, roughly 3.1 kg | Not applicable |
| Gastrointestinal symptoms reported | About 28% | About 16% |
That table is the centre of this page. In the Diabetes Prevention Program, metformin produced a real, durable weight reduction, and a small one. The highly adherent subgroup, meaning people who took it consistently for years, reached about three and a half percent.
There is a second caveat in the other direction. The DPP population was people with prediabetes, and in that population metformin also reduced progression to diabetes. For a patient whose fasting glucose has started drifting, weight is not the only outcome on the table.
The figures below are per-tablet prices read from Watsons Philippines product pages in August 2026, all prescription required and all flagged VAT exempt on the listing page.
| Product | Form | Per tablet | Source |
|---|---|---|---|
| Watsons Generics metformin | Immediate release | ₱4.00 | Watsons PH product page, August 2026 |
| RiteMED metformin | Immediate release | ₱4.25 | Watsons PH product page, August 2026 |
| Glumet XR | Extended release | ₱14.25 | Watsons PH product page, August 2026 |
| Glucophage XR | Extended release | ₱18.50 | Watsons PH product page, August 2026 |
| Glucophage | Immediate release | ₱19.00 | Watsons PH product page, August 2026 |
Per-tablet listings only, from one retailer, dated. They are not a dosing recommendation and not a quote, and pharmacy pricing moves.
One thing falls out of that table: on the Watsons listings, branded Glucophage costs between four and five times the plain generic per tablet for the same molecule at the same strength, which is a larger gap than many patients expect and worth raising with the prescriber.
Metformin has one dominant tolerability story: nausea, loose stools, abdominal cramping and a metallic taste, most noticeable when the drug is started.
The Diabetes Prevention Program quantified it in a population that was otherwise well. Gastrointestinal symptoms were reported by about 28 percent of metformin participants against about 16 percent of those on placebo. Symptoms specifically attributed to the study medication ran at 9.5 percent against 1.1 percent. Those rates declined across the trial, and by years six through nine the metformin and placebo groups looked similar.
Extended-release formulations release the drug more gradually. The Philippine market carries several, including the Glumet XR and Glucophage XR listings above.
Beyond the gut, the prescribing discussion covers kidney function, alcohol intake, the lactic acidosis question, long-term vitamin B12 status, and holding the drug around iodinated contrast imaging. Those are screening and monitoring questions, and they are a large part of why this molecule is prescription controlled despite its low per-tablet price.
A short section, because clearing away the wrong expectations is most of the value this page can offer.
Because metformin is prescription only and its weight use is off-label, the legitimate route runs through a licensed Philippine physician. That consultation goes better with the right material:
Nothing on this page is medical advice, a diagnosis, a dose, or a recommendation to take any medicine. Prices are market observations from a named retailer on the month stated and will move, and prescribing belongs with a licensed Philippine physician.
No. Metformin’s labelled indication is type 2 diabetes mellitus, and it is sold in the Philippines as a prescription medicine. Use of it purely to reduce body weight in a person without diabetes is off-label, which means the prescriber is going outside the labelled indication on their own clinical judgement. That is not the same as approval, and prescribing belongs with a licensed Philippine physician.
Modest amounts. In the Diabetes Prevention Program, a trial in adults with prediabetes, participants on metformin lost about 2.1 percent of body weight, roughly 2.7 kg at one year, and in the long-term follow-up study that settled at about 2.0 percent, close to 1.9 kg, held over as long as ten years. Highly adherent participants reached about 3.5 percent. In the same programme, gastrointestinal symptoms were reported by about 28 percent of metformin participants against about 16 percent on placebo.
Watsons Philippines’ product pages, checked in August 2026, list RiteMED metformin 500mg at PHP 4.25 a tablet, Watsons Generics metformin 500mg at PHP 4.00 a tablet and branded Glucophage 500mg at PHP 19.00 a tablet, all prescription only and flagged VAT exempt.
In the Diabetes Prevention Program, gastrointestinal symptoms were reported by about 28 percent of metformin participants against about 16 percent on placebo, and symptoms attributed to the study drug ran at 9.5 percent against 1.1 percent. Those rates declined over the trial and by years six to nine the two groups looked similar. Extended-release formulations exist partly for people in whom the symptoms do not fade, and any switch is a decision for the prescriber.
